EUVIMEDEUVIMED entdecken
Crossref

Co-targeting 26S proteasome and mGluR1 using bortezomib and riluzole suppresses the progression of androgen-independent prostate cancer

Ahmed S Alhallaq iD, Nadeen S Sultan, Heba Alwasify, Yasser M Elsherbini, Mohamed E Abdraboh

Medical Oncology · 04.11.2026 · 43 (12)

DOI: 10.1007/s12032-026-03464-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, online erschienen am 04.11.2026. Verfasst von Ahmed S Alhallaq und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology, Histology and Genetics Division, Zoology Department, Faculty of Science, Mansoura University, Mansoura, Egypt. ahmdhallag@gmail.com. Hauptthemen laut MEDLINE: Bortezomib, Riluzole, Receptors, Metabotropic Glutamate, Proteasome Endopeptidase Complex. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of NF-κB signaling and dysregulation of mGluR1 contribute to prostate cancer (PCa) progression and the development of castration-resistant prostate cancer (CRPC), for which effective therapeutic options remain limited due to treatment resistance and toxicity. This study aimed to investigate the therapeutic potential of combined inhibition of 26S proteasome-mediated NF-κB signaling and mGluR1 in androgen-independent CRPC. Human CRPC cells were treated with the 26S proteasome inhibitor bortezomib combined with the mGluR1 inhibitor riluzole to assess their effects on cell proliferation, apoptosis, stemness, and migration. The experimental protocol included MTT, the Chou-Talalay model for combination index, wound healing, colony formation, RT-qPCR, ELISA, and western blot analyses. Public PCa datasets were analyzed to validate the biological and clinical relevance of the investigated NF-κB-mGluR1-associated targets. The combination of bortezomib and riluzole synergistically inhibited CRPC cell growth (CI=0.58), and the antiproliferative effect coincided with a significant reduction in CRPC colony formation. Gene and protein expression analyses showed that the combination treatment suppressed NF-κB activity and mGluR1 signaling, thereby downregulating multiple molecular mediators associated with PCa progression. Additionally, this combination significantly reduced TNF-α levels, increased the BAX/Bcl-2 ratio, and induced apoptosis in CRPC cells. Gene expression analysis indicated that the combined treatment reduced the expression of cancer stem cell markers, including Sox2, NANOG, CD44, and MDR1. Furthermore, the combination reduced IL-6 levels, a pro-inflammatory cytokine associated with CRPC stemness and metastasis. The combined treatment notably decreased CRPC cell migration, as confirmed by a wound healing assay and significant reductions in the expression of VEGFA and CD44, as well as the concentration of MMP-9. Bioinformatic analyses further supported the clinical relevance of the investigated molecular targets. These findings demonstrate that simultaneous targeting of 26S proteasome-mediated NF-κB signaling and mGluR1 effectively suppresses multiple hallmarks of CRPC progression and represents a promising therapeutic strategy for advanced PCa. Graphic Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BortezomibRiluzoleReceptors, Metabotropic GlutamateProteasome Endopeptidase ComplexProstatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsMaleHumansApoptosisCell Line, TumorCell ProliferationSignal TransductionNF-kappa BDisease ProgressionCell Movement

Stichwörter der Autor:innen

26S proteasomeGlutamateNF-κBProstate cancermGluR1

Substanzen

BortezomibRiluzolemetabotropic glutamate receptor type 1Receptors, Metabotropic GlutamateProteasome Endopeptidase ComplexATP dependent 26S proteaseNF-kappa B

Autor:innen und Institutionen

  • Cell Biology, Histology and Genetics Division, Zoology Department, Faculty of Science, Mansoura University, Mansoura, Egypt. ahmdhallag@gmail.com.
  • Cell Biology, Histology and Genetics Division, Zoology Department, Faculty of Science, Mansoura University, Mansoura, Egypt.
  • Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
  • Biology Department, Faculty of Science, New Mansoura University, Mansoura, Egypt.

ORCID-Profile: Ahmed S Alhallaq

Zitieren

APA

Alhallaq, A. S., Sultan, N. S., Alwasify, H., Elsherbini, Y. M., & Abdraboh, M. E. (2026). Co-targeting 26S proteasome and mGluR1 using bortezomib and riluzole suppresses the progression of androgen-independent prostate cancer. Medical Oncology, 43(12). https://doi.org/10.1007/s12032-026-03464-7

Vancouver

Alhallaq AS, Sultan NS, Alwasify H, Elsherbini YM, Abdraboh ME. Co-targeting 26S proteasome and mGluR1 using bortezomib and riluzole suppresses the progression of androgen-independent prostate cancer. Medical Oncology. 2026;43(12). doi:10.1007/s12032-026-03464-7

BibTeX
@article{Alhallaq2026,
  author = {Alhallaq, Ahmed S and Sultan, Nadeen S and Alwasify, Heba and Elsherbini, Yasser M and Abdraboh, Mohamed E},
  title = {Co-targeting 26S proteasome and mGluR1 using bortezomib and riluzole suppresses the progression of androgen-independent prostate cancer},
  journal = {Medical Oncology},
  year = {2026},
  volume = {43},
  number = {12},
  doi = {10.1007/s12032-026-03464-7}
}
Kostenlos starten →